Kinesiophobia Scale for the Upper Extremity
Launched by EMRE ŞENOCAK · Jun 27, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding kinesiophobia, which is the fear of movement that can affect people with shoulder injuries. Researchers want to create a new questionnaire specifically for people dealing with shoulder pain, as current questionnaires don’t address their needs. The goal is to better evaluate how this fear impacts their recovery and treatment.
To participate in the study, individuals aged 65 to 74 who have specific shoulder issues and score above 37 on an existing kinesiophobia test may be eligible. Participants will attend two meetings where they will answer questions about their experiences; the first meeting will take place soon after joining the study, and the second will happen within a week. It's important to note that individuals with certain conditions, such as cancer or those who have recently received physical therapy, cannot participate. This study aims to improve understanding of how fear of movement affects recovery from shoulder injuries, which could lead to better support and treatment options for patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Tampa Kinesiophobia Score \>37 points
- • Presence of traumatological, orthopedic and rheumatological pathology in the upper extremity
- • Mini-Mental State Examination score \>24 points
- Exclusion Criteria:
- • Malignancy,
- • Psychiatric drug use,
- • Use of painkillers during evaluation periods,
- • Those who received physiotherapy before the study (last 6 months),
- • Those whose education level is below secondary school level,
About Emre şenocak
Emre Şenocak is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, Emre Şenocak collaborates with leading researchers and healthcare institutions to design and implement rigorous clinical studies. By prioritizing ethical standards, patient safety, and scientific integrity, the organization aims to accelerate the development of groundbreaking treatments across various therapeutic areas, ultimately contributing to the enhancement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
İstanbul, , Turkey
Patients applied
Trial Officials
Abdurrahman Tanhan, PhD
Study Chair
Bitlis Eren University
Zeynep Hoşbay, Associate Professor
Study Chair
Biruni University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported